Literature DB >> 6409485

Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes.

R C Bast, E L Reinherz, C Maver, P Lavin, S F Schlossman.   

Abstract

The cell surface phenotype of human peripheral blood mononuclear cells has been characterized before and after intravenous injection of cyclophosphamide or prednisolone. Low doses of cyclophosphamide (100-600 mg/m2) temporarily decrease levels of circulating B lymphocytes. Slightly higher doses of cyclophosphamide (200-600 mg/m2) produce transient depression of T8-, M1-, and Ia-positive cells. After doses of 200-400 mg cyclophosphamide/m2, T4-positive cells are spared, resulting in a transient elevation of the T4/T8 ratio. With higher doses of cyclophosphamide (greater than or equal to 600 mg/m2), all T cells are affected and the T4/T8 ratio declines to pretreatment levels. By contrast, intravenous injection of prednisolone at 40 mg/m2 reduces the T4/T8 ratio. Levels of both T4 and T8 cells decline, but T4 cells are affected more markedly than T8 cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409485     DOI: 10.1016/0090-1229(83)90193-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  11 in total

Review 1.  Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.

Authors:  P Gergely
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men.

Authors:  M K Maini; R J Gilson; N Chavda; S Gill; A Fakoya; E J Ross; A N Phillips; I V Weller
Journal:  Genitourin Med       Date:  1996-02

Review 3.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

4.  Coincident change of cellular function and phenotype in the course of a suppressor T cell acute lymphocytic leukaemia.

Authors:  G Sieber; W D Ludwig; H Teichmann; F Herrmann; H Rühl
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

5.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

Review 6.  Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy.

Authors:  M Hernberg
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

7.  Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults.

Authors:  A Mukherjee; M Helbert; W D J Ryder; R Borrow; J R E Davis; S M Shalet
Journal:  Clin Exp Immunol       Date:  2009-02-10       Impact factor: 4.330

Review 8.  Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.

Authors:  Michael J Bradshaw; Tracey A Cho; Felicia C Chow
Journal:  Rheum Dis Clin North Am       Date:  2017-08-23       Impact factor: 2.670

9.  Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.

Authors:  T M Tuttle; M D Fleming; P S Hogg; T H Inge; H D Bear
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

10.  Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient.

Authors:  Ruby Kochhar; Jay N Umbreit
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.